Literature DB >> 3257998

A simplified assay for the detection of C3a in human plasma employing a monoclonal antibody raised against denatured C3.

B Nilsson1, K E Svensson, M Inganäs, U R Nilsson.   

Abstract

A monoclonal antibody raised against SDS-denatured C3 was shown to react with both solid-phase C3a and unfragmented C3. However, in the fluid phase the antibody was found to bind only to C3a and not to native C3. These findings indicated that the antibody could be used in an assay to detect C3a in human EDTA-plasma without prior separation of C3a from native C3. A simple and rapid competition ELISA was developed which monitored soluble C3a. 200 microliter of C3a (8 ng) was absorbed to plastic wells over night at 4 degrees C. Thereafter, 50 microliter of sample and 50 microliter of constant amounts of monoclonal antibody conjugated with beta-galactosidase, were incubated for 60 min at 37 degrees C. After washing, the colour reaction was started by adding nitrophenyl-galactopyridine to the wells. The microtitre plate was incubated at 37 degrees C for 30 min and the staining intensity was quantified at 405 nm. The assay detected both C3a and C3ades arg. A strong correlation was obtained between the new technique and an RIA which used an acid precipitation step for the separation of C3a prior to the determination of C3a (r = 0.9). Significantly higher levels of C3a were detected both in plasma from patients with immune complexes (93 +/- 9 ng/ml; P less than 0.1) and in plasma from patients treated in blood oxygenators (140 +/- 19 ng/ml; P less than 0.05) than in plasma from normal subjects (74 +/- 4 ng/ml). The results were not affected by repeated freezing and thawing of the plasma samples.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257998     DOI: 10.1016/0022-1759(88)90229-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  7 in total

1.  Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1.

Authors:  Osama A Hamad; Per H Nilsson; Diana Wouters; John D Lambris; Kristina N Ekdahl; Bo Nilsson
Journal:  J Immunol       Date:  2010-02-05       Impact factor: 5.422

2.  Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles.

Authors:  Yvonne Klapper; Osama A Hamad; Yuji Teramura; Gero Leneweit; G Ulrich Nienhaus; Daniel Ricklin; John D Lambris; Kristina N Ekdahl; Bo Nilsson
Journal:  Biomaterials       Date:  2014-01-23       Impact factor: 12.479

3.  Tubing loops as a model for cardiopulmonary bypass circuits: both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model.

Authors:  J Gong; R Larsson; K N Ekdahl; T E Mollnes; U Nilsson; B Nilsson
Journal:  J Clin Immunol       Date:  1996-07       Impact factor: 8.317

4.  The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb).

Authors:  Fredrik Bexborn; Per Ola Andersson; Hui Chen; Bo Nilsson; Kristina N Ekdahl
Journal:  Mol Immunol       Date:  2007-12-21       Impact factor: 4.407

5.  Blood Compatibility of Sulfonated Cladophora Nanocellulose Beads.

Authors:  Igor Rocha; Jonas Lindh; Jaan Hong; Maria Strømme; Albert Mihranyan; Natalia Ferraz
Journal:  Molecules       Date:  2018-03-07       Impact factor: 4.411

6.  Assessment of the Role of C3(H2O) in the Alternative Pathway.

Authors:  Karin Fromell; Anna Adler; Amanda Åman; Vivek Anand Manivel; Shan Huang; Claudia Dührkop; Kerstin Sandholm; Kristina N Ekdahl; Bo Nilsson
Journal:  Front Immunol       Date:  2020-03-31       Impact factor: 7.561

Review 7.  Current and Future Approaches for Monitoring Responses to Anti-complement Therapeutics.

Authors:  Maedeh Mohebnasab; Oskar Eriksson; Barbro Persson; Kerstin Sandholm; Camilla Mohlin; Markus Huber-Lang; Brendan J Keating; Kristina N Ekdahl; Bo Nilsson
Journal:  Front Immunol       Date:  2019-11-08       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.